Bulls vs Bears updated 6/18/15
Bullish- Incentive plan for new CEO (see news dated 10/15/14)
- 2015 commercialization efforts will focus initially on breast cancer, melanoma, and oral cavity head and neck cancers \
- Expects to achieve break-even cash flow in first quarter 2016
- Guidance for Lymphoseek revenue in 2015 is $10 million to $12 million ($4.2 million in Y 2014); over 100% increase.
- Lymphoseek®Phase 3 NEO3-06 Clinical Trial in Oral Cavity Cancer of the Head and Neck met primary goal;
- European Commission Approves Navidea’s Sentinel Lymph Node Detection Agent Lymphoseek® on 11/20/14
- fTcSC caused statistically significant greater levels of pain after injection compared to Lymphoseek
- As of 6/2/15 Insider buy 3 mo 129,355, Buy/Tot 9/13; 12 mo 290,375, Buy/Tot 25/32)
Bearish
- Expensive term loan ($50 million) with CRG (A term of six years, an interest only period for the first four years, and a 14% annual interest rate) see news dated 5/11/15,
- NAV 4694 F-18 PET for AD) on hold pending partner
- NAV5001 (I-123) radiolabeled SPECT for PD, program terminated with Alseres Pharm.
No comments:
Post a Comment